Literature DB >> 24320694

Controlled porosity osmotic pump system for the delivery of diclofenac sodium: in-vitro and in-vivo evaluation.

Laila H Emara1, Nesrin F Taha, Ahmed A El-Ashmawy, Hala M Raslan, Nadia M Mursi.   

Abstract

The objective of this study was to develop controlled porosity osmotic pump (CPOP) tablets of diclofenac sodium (DS). The influence of different cores (polymers and osmogens) and coats (thickness and porosigen content) on DS release were studied. Results revealed that decreasing HPMC viscosity grade from 4000cp (K4M) to 15cp (E15) increased DS release. While increasing the tablet coat thickness decreased DS release. The presence of osmogen increased DS release in the following rank: mannitol > lactose > avicel. There was a direct relationship between increasing PEG-400 in the coating solution and the amount of drug released in all formulations studied, except in one condition. A comparative bioavailability study using a selected CPOP formulation (T) versus the innovator product (R) revealed that CPOP tablet maintained a less fluctuated DS plasma concentration for up to 24 h with a detected mean Cmax of 836.8 ± 142.4 and 445.0 ± 81.0 ng/mL for R and T, respectively. There were no statistically significant differences between R and T, concerning AUC0-24 and AUC0-∞. Moreover, the appearance of the multi-peak phenomenon, which is frequently observed with DS absorption, was found in only 25% of volunteers in case of T versus 75% in case of R.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24320694     DOI: 10.3109/10837450.2013.823990

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  1 in total

1.  Redefinition to bilayer osmotic pump tablets as subterranean river system within mini-earth via three-dimensional structure mechanism.

Authors:  Abi Maharjan; Hongyu Sun; Zeying Cao; Ke Li; Jinping Liu; Jun Liu; Tiqiao Xiao; Guanyun Peng; Junqiu Ji; Peter York; Balmukunda Regmi; Xianzhen Yin; Jiwen Zhang; Li Wu
Journal:  Acta Pharm Sin B       Date:  2021-11-13       Impact factor: 14.903

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.